We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Akari Therapeutics PLC | NASDAQ:AKTX | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.005 | -0.42% | 1.185 | 1.15 | 1.52 | 1.20 | 1.17 | 1.19 | 10,002 | 22:16:11 |
|
UNITED STATES SECURITIES
|
OMB APPROVAL
OMB Number: 3235-0076
Estimated Average burden hours per response: 4.0
|
Notice of Exempt Offering of Securities
|
1. Issuer's Identity | ||
CIK (Filer ID Number) | Previous Name(s) o None | Entity Type |
0001541157
|
Celsus Therapeutics Plc.
Morria Biopharmaceuticals PLC
|
x
Corporation
o
Limited Partnership
o
Limited Liability Company
o
General Partnership
o
Business Trust
o
Other
|
Name of Issuer | ||
Akari Therapeutics Plc
|
||
Jurisdiction of Incorporation/Organization | ||
UNITED KINGDOM | ||
Year of Incorporation/Organization | |||
x | Over Five Years Ago | ||
o | Within Last Five Years (Specify Year) | ||
o | Yet to Be Formed |
2. Principal Place of Business and Contact Information | ||||
Name of Issuer | ||||
Akari Therapeutics Plc |
Street Address 1 | Street Address 2 | ||
75/76 WIMPOLE STREET |
City | State/Province/Country | ZIP/Postal Code | Phone No. of Issuer |
LONDON | UNITED KINGDOM | W1G 9RT | +44 20 8004 0270 |
3. Related Persons |
Last Name | First Name | Middle Name |
Richardson | Clive |
Street Address 1 | Street Address 2 |
c/o Akari Therapeutics, PLC | 75/76 Wimpole Street |
City | State/Province/Country | ZIP/Postal Code |
London | UNITED KINGDOM | W1G 9RT |
Relationship: | x | Executive Officer | x | Director | o | Promoter |
Clarification of Response (if Necessary) | |
Last Name | First Name | Middle Name |
Elefant | Dov |
Street Address 1 | Street Address 2 |
c/o Akari Therapeutics, PLC | 75/76 Wimpole Street |
City | State/Province/Country | ZIP/Postal Code |
London | UNITED KINGDOM | W1G 9RT |
Relationship: | x | Executive Officer | x | Director | o | Promoter |
Clarification of Response (if Necessary) | |
Last Name | First Name | Middle Name |
Prudo | Ray |
Street Address 1 | Street Address 2 |
c/o Akari Therapeutics, PLC | 75/76 Wimpole Street |
City | State/Province/Country | ZIP/Postal Code |
London | UNITED KINGDOM | W1G 9RT |
Relationship: | x | Executive Officer | x | Director | o | Promoter |
Clarification of Response (if Necessary) | |
Last Name | First Name | Middle Name |
Hill | James |
Street Address 1 | Street Address 2 |
c/o Akari Therapeutics, PLC | 75/76 Wimpole Street |
City | State/Province/Country | ZIP/Postal Code |
London | UNITED KINGDOM | W1G 9RT |
Relationship: | o | Executive Officer | x | Director | o | Promoter |
Clarification of Response (if Necessary) | |
Last Name | First Name | Middle Name |
Ungar | Stuart |
Street Address 1 | Street Address 2 |
c/o Akari Therapeutics, PLC | 75/76 Wimpole Street |
City | State/Province/Country | ZIP/Postal Code |
London | UNITED KINGDOM | W1G 9RT |
Relationship: | o | Executive Officer | x | Director | o | Promoter |
Clarification of Response (if Necessary) | |
Last Name | First Name | Middle Name |
Byrne | David |
Street Address 1 | Street Address 2 |
c/o Akari Therapeutics, PLC | 75/76 Wimpole Street |
City | State/Province/Country | ZIP/Postal Code |
London | UNITED KINGDOM | W1G 9RT |
Relationship: | o | Executive Officer | x | Director | o | Promoter |
Clarification of Response (if Necessary) | |
Last Name | First Name | Middle Name |
Williams | Donald |
Street Address 1 | Street Address 2 |
c/o Akari Therapeutics, PLC | 75/76 Wimpole Street |
City | State/Province/Country | ZIP/Postal Code |
London | UNITED KINGDOM | W1G 9RT |
Relationship: | o | Executive Officer | x | Director | o | Promoter |
Clarification of Response (if Necessary) | |
Last Name | First Name | Middle Name |
Grissinger | Michael |
Street Address 1 | Street Address 2 |
c/o Akari Therapeutics, PLC | 75/76 Wimpole Street |
City | State/Province/Country | ZIP/Postal Code |
London | UNITED KINGDOM | W1G 9RT |
Relationship: | o | Executive Officer | x | Director | o | Promoter |
Clarification of Response (if Necessary) | |
Last Name | First Name | Middle Name |
Feldschreiber | Peter |
Street Address 1 | Street Address 2 |
c/o Akari Therapeutics, PLC | 75/76 Wimpole Street |
City | State/Province/Country | ZIP/Postal Code |
London | UNITED KINGDOM | W1G 9RT |
Relationship: | o | Executive Officer | x | Director | o | Promoter |
Clarification of Response (if Necessary) | |
4. Industry Group |
o | Agriculture | Health Care | o | Retailing | ||||
Banking & Financial Services | x | Biotechnology | o | Restaurants | ||||
o | Commercial Banking | o | Health Insurance | Technology | ||||
o | Insurance | o | Hospitals & Physicians | o | Computers | |||
o | Investing | o | Pharmaceuticals | o | Telecommunications | |||
o | Investment Banking | o | Other Health Care | o | Other Technology | |||
o |
Pooled Investment Fund
|
Travel | ||||||
o | Other Banking & Financial Services | o | Manufacturing | o | Airlines & Airports | |||
Real Estate | o | Lodging & Conventions | ||||||
o | Commercial | o | Tourism & Travel Services | |||||
o | Construction | o | Other Travel | |||||
o | REITS & Finance | o | Other | |||||
o | Residential | |||||||
o | Other Real Estate | |||||||
o | Business Services | |||||||
Energy | ||||||||
o | Coal Mining | |||||||
o | Electric Utilities | |||||||
o | Energy Conservation | |||||||
o | Environmental Services | |||||||
o | Oil & Gas | |||||||
o | Other Energy |
5. Issuer Size |
Revenue Range | Aggregate Net Asset Value Range | ||
o | No Revenues | o | No Aggregate Net Asset Value |
o | $1 - $1,000,000 | o | $1 - $5,000,000 |
o | $1,000,001 - $5,000,000 | o | $5,000,001 - $25,000,000 |
o | $5,000,001 - $25,000,000 | o | $25,000,001 - $50,000,000 |
o | $25,000,001 - $100,000,000 | o | $50,000,001 - $100,000,000 |
o | Over $100,000,000 | o | Over $100,000,000 |
x | Decline to Disclose | o | Decline to Disclose |
o | Not Applicable | o | Not Applicable |
6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply) |
o | Rule 504(b)(1) (not (i), (ii) or (iii)) | o | Rule 505 | |||
o | Rule 504 (b)(1)(i) | x | Rule 506(b) | |||
o | Rule 504 (b)(1)(ii) | o | Rule 506(c) | |||
o | Rule 504 (b)(1)(iii) | o | Securities Act Section 4(a)(5) | |||
o | Investment Company Act Section 3(c) |
7. Type of Filing |
x | New Notice | Date of First Sale | 2019-06-28 | o | First Sale Yet to Occur |
o | Amendment |
8. Duration of Offering |
Does the Issuer intend this offering to last more than one year? | o | Yes | x | No |
9. Type(s) of Securities Offered (select all that apply) |
o | Pooled Investment Fund Interests | o | Equity |
o | Tenant-in-Common Securities | o | Debt |
o | Mineral Property Securities | x | Option, Warrant or Other Right to Acquire Another Security |
x | Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security | o | Other (describe) |
10. Business Combination Transaction |
Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? | o | Yes | x | No |
Clarification of Response (if Necessary) | ||||
11. Minimum Investment |
Minimum investment accepted from any outside investor | $ 0 USD |
12. Sales Compensation |
Recipient | Recipient CRD Number | o | None | ||
Paulson Investment Company, LLC | 5670 | ||||
(Associated) Broker or Dealer | x | None | (Associated) Broker or Dealer CRD Number | x | None |
Street Address 1 | Street Address 2 | ||||
2141 W. NORTH AVE. | 2ND FLOOR |
City | State/Province/Country | ZIP/Postal Code |
CHICAGO | ILLINOIS | 60647 |
State(s) of Solicitation | o | All States | x | Foreign/Non-US |
ALABAMA
ARIZONA CALIFORNIA COLORADO CONNECTICUT FLORIDA ILLINOIS KANSAS MARYLAND MASSACHUSETTS MICHIGAN MINNESOTA NEVADA NEW HAMPSHIRE NEW JERSEY NEW MEXICO NEW YORK OHIO PENNSYLVANIA TEXAS VIRGINIA WASHINGTON |
13. Offering and Sales Amounts |
Total Offering Amount | $ 4499945 USD | o Indefinite |
Total Amount Sold | $ 4499945 USD | |
Total Remaining to be Sold | $ 0 USD | o Indefinite |
Clarification of Response (if Necessary) |
The warrants and shares underlying the warrants, the subject matter of this Form D were issued in connection with an offering of (i) 2,368,392 ADSs issued in a registered direct offering, and (ii) unregistered warrants to purchase 1,184,213 ADSs. |
14. Investors |
o |
Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
Number of such non-accredited investors who already have invested in the offering |
|
Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering: | 45 |
15. Sales Commissions & Finders' Fees Expenses |
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
|
Sales Commissions | $ 337496 USD | o | Estimate |
Finders' Fees | $ 0 USD | o | Estimate |
Clarification of Response (if Necessary) |
Paulson Investment Company, LLC is also entitled to expense reimbursement of up to $50,000, a non-accountable expense allowance of $10,000 and warrants to purchase an aggregate of 177,629 ADSs exercisable at $2.85 per ADS for five years. |
16. Use of Proceeds |
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
|
$ 0 USD | o | Estimate |
Clarification of Response (if Necessary) |
Issuer expects to use proceeds from the offering to fund its ongoing research and clinical development efforts and for working capital and general corporate purposes. |
Signature and Submission |
Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice. |
Terms of Submission |
In submitting this notice, each Issuer named above is: | ||
|
Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person. | |
For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature. |
Issuer | Signature | Name of Signer | Title | Date |
Akari Therapeutics Plc | /s/ Clive Richardson | Clive Richardson | Interim Chief Executive Officer and Chief Operating Officer | 2019-07-12 |
1 Year Akari Therapeutics Chart |
1 Month Akari Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions